Table 1 Homogeneity and comparison of demographic data and comorbidities between groups.

From: Predictive study of pharmacological reversal for residual neuromuscular blockade and postoperative pulmonary complications: a prospective, observational, cohort study

Quantitative variables (n)

Cisatracurium—no reversal group

n = 176

Cisatracurium + neostigmine group

n = 112

Rocuronium—no reversal group

n = 276

Rocuronium + sugammadex group

n = 150

P-value

Mean

SD

Mean

SD

Mean

SD

Mean

SD

ANOVA

Age; years (714)

59.8

17.3

60.8

16.7

60.7

16.3

59.4

15.5

0.81

Weight; kg (714)

70.2

11.9

72.6

12.5

72.1

13.2

75.4

16.8

0.11

ASA Score (714)

2.10

0.69

2.16

0.71

2.11

0.67

2.14

0.66

0.89

Qualitative variables (n)

Percent % (n)

Percent % (n)

Percent % (n)

Percent % (n)

χ2 test

    

Male (474)

23.2% (110)

16.2% (77)

40.1% (190)

20.4% (97)

0.49

    

Female (240)

27.5% (66)

14.5% (35)

35.8% (86)

22.1% (53)

    

COPD (85)

21.1% (18)

16.4% (14)

49.4% (42)

12.9% (11)

0.09

    

OSAS (32)

40.6% (13)

3.10% (1)

34.3% (11)

21.8% (7)

0.07

    

Restrictive lung disease (8)

12.5% (1)

25.0% (2)

25.0% (2)

37.5% (3)

0.49

    

Asthma (14)

35.7% (5)

0.00% (0)

42.8% (6)

21.4% (3)

0.38

    

AMI (67)

22.3% (15)

23.8% (16)

35.8% (24)

17.9% (12)

0.28

    

Heart failure (20)

20.0% (4)

15.0% (3)

40.0% (8)

25.0% (5)

0.94

    

High blood pressure (329)

26.4% (87)

17.6% (58)

37.9% (125)

17.9% (59)

0.16

    

Anaemia (62)

30.6% (19)

17.7% (11)

35.4% (22)

16.1% (10)

0.54

    

Chronic renal failure (40)

37.5% (15)

17.5% (7)

27.5% (11)

17.5% (7)

0.20

    

DM (131)

23.6% (31)

21.3% (28)

36.6% (48)

18.3% (24)

0.25

    

Dyslipidemia (165)

24.2% (40)

18.7% (31)

37.5% (62)

19.3% (62)

0.64

    

Hyperthyroidism (4)

0.00% (0)

25.0% (1)

50.0% (2)

25.0% (1)

0.71

    

Hypothyroidism (2)

27.2% (6)

13.6% (3)

45.4% (10)

13.6% (3)

0.80

    

Chronic liver disease (20)

35.0% (7)

20.0% (4)

20.0% (4)

25.0% (5)

0.36

    

Dementia (2)

0.00% (0)

0.00% (0)

0.00% (0)

100% (2)

0.05

    

Fragility (114)

20.1% (23)

17.5% (20)

43.8% (50)

18.4% (21)

0.42

    
  1. Basic descriptives and tests for the demographic and comorbidity variables for each group. As can be seen, there was no significant relationship between the demographic and comorbidity variables and each group. Absolute (N) and relative (%) frequencies along with independence tests (χ2) for the qualitative variables, and mean and standard deviation (SD) along with comparing means tests (analysis of variance [ANOVA]) for the quantitative variables. *Significance defined as p-value < 0.05.
  2. ASA, American Society of Anesthesiologists score; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome; AMI, acute myocardial infarction; DM, diabetes mellitus.
Back to article page